Apolipoprotein C3 (APOC3) Antibody (HRP)

Este producto es parte de APOC3 - Apolipoprotein C3
Product Graph
169€ (20 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Apolipoprotein C3 (APOC3) Antibody (HRP)
category
Primary Antibodies
provider
Abbexa
reference
abx107991
tested applications
ELISA

Description

Apolipoprotein C-III Antibody (HRP) is a Rabbit Primary antibodies antibody against Apolipoprotein C-III conjugated to HRP.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Apolipoprotein C3 (APOC3)
Host
Rabbit
Reactivity
Human
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
HRP
Isotype
IgG
Purity
> 95%
Purification
Purified by Protein G.
Size 1
20 µg
Size 2
50 µg
Size 3
100 µg
Size 4
200 µg
Size 5
1 mg
Form
Liquid
Tested Applications
ELISA
Buffer
0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P02656
Gene ID
345
OMIM
107720
Alias
APOC3, APOCIII, HALP2, apolipoprotein C3, Apo-C3, ApoC-3,apo-CIII, and apolipoprotein C-III
Background
Antibody anti-APOC3
Status
RUO

Descripción

APOC3 is a critical regulator of triglyceride-rich lipoprotein (TRL) metabolism, primarily associated with VLDL, HDL, and chylomicrons. APOC3 inhibits lipoprotein lipase (LPL) and hepatic uptake of remnant lipoproteins by interfering with the binding of TRLs to heparan sulfate proteoglycans (HSPG) and the low-density lipoprotein receptor (LDLR). Elevated APOC3 levels are strongly associated with hypertriglyceridemia, atherogenic dyslipidemia, and increased risk of cardiovascular disease. APOC3 expression is regulated by dietary factors, insulin, and nuclear receptors such as PPAR-alpha. Loss-of-function mutations in the APOC3 gene result in lower plasma triglycerides and reduced cardiovascular risk, highlighting its potential as a therapeutic target for lipid disorders. APOC3 also modulates inflammatory responses and has been implicated in non-alcoholic fatty liver disease (NAFLD), where elevated levels contribute to hepatic lipid accumulation. Pharmacological inhibitors of APOC3, such as antisense oligonucleotides, are being developed to lower plasma triglycerides and improve lipid profiles in hyperlipidemic patients.

Related Products

EH0611

Human APOC3 (Apolipoprotein C-III) ELISA Kit

Ver Producto
P4438

Recombinant Human APOC3

Ver Producto
QT-EH0611

Human APOC3 (Apolipoprotein C-III) QuickTest ELISA Kit

Ver Producto